SPI-ESTEROID SYSTEMS WITH NEUROACTIVE AND ANTI-INFLAMMATORY EFFECTS
Argentina Patent
Stats

Importance
| AR Family Size
|
Non-US Coverage
|
Abstract
These molecular entities have anti-glutamatergic and anti-inflammatory action, usable in the treatment of chronic and acute inflammatory diseases, neurodegenerative, neuropsychiatric and neurological. Claim 1: Spiro-steroid systems with neuroactive and anti-inflammatory effects derived from diosgenin, hecogenin and solasodine with spirostanic rings fused to their structure, for use as drugs in medicine, of the group of general formula (1), (2), ( 3) and (4) in all their configurations and natural conformations, where for the compounds of general formulas (1), (2), (3) and (4), R¹, R² and R⁴ represents H, hydroxyl group, ketal, alkoxy, alkanoyloxy, alkenyloxy and alkoxycarbonyloxy (preferably alkyl groups of up to 8 straight or branched chain carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl and octyl, and the chain isomers of all of the above) ; R¹, R² and R⁴ also represent an amino group, preferably substituted with alkylamino, dialkylamino, alkenylamino, dialkenylamino, aminocarbonyloxy, alkylamino and dialkylamino groups. The alkyl groups will preferably have up to 8 straight or branched chain carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl and octyl, and the chain isomers of all of the foregoing; R¹, R² and R⁴ also represent amido, thiols, sulfinyls, sulfonamides and sulfonyl groups. The sulfonyls groups are preferably substituted with alkylaryls, alkanoyloxyaryls, alkenyloxyaryls and alkenylaryls. The alkyl groups will preferably have up to 8 straight or branched chain carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl and octyl, and the chain isomers of all of the foregoing; R¹, R² and R⁴ also represent cyano, thiocyan, isothiocyano groups, preferentially substituted with alkyl, azidoalkyl, alkanoyloxyalkyl, arylalkyl, heteroarylalkyl, arylalkyl, heteroarylalkyl, arylalkyl, arylalkylalkyl, alkanoyloxy-alkylaryloxy, alkylalkyl-alkylaryloxy-alkylaryloxy-alkylalkyl-alkylaryloxy-alkylaryloxy-alkylaryloxy-alkylaryloxy-alkylaryl-alkylaryloxy-alkylalkyl-alkylaryloxy-alkylaryl-alkylaryloxy-alkylaryloxy-alkylaryloxy-alkylaryloxy-alkylaryloxy-alkylaryloxylalkyl groups. Cyanoalkynyl substituents may in turn be substituted by heteroarylalkyls, hydroxyalkyls, alkoxyalkyls, aminoalkyls and acyloaminoalkyls. The alkyl groups will preferably have up to 8 straight or branched chain carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl and octyl, and the chain isomers of all of the foregoing; R¹, R² and R⁴ also represent a phosphoryl group, preferably substituted with alkylaryls, alkanoyloxyaryls, alkenyloxyaryls and alkenyryls. The alkyl groups will preferably have up to 8 straight or branched chain carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl and octyl, and the chain isomers of all of the foregoing; for the compounds of general formula (1), (2), (3) and (4), R³ represents H and hydroxyl group; for the compounds of the general formula (1), (2), (3) and (4), R⁵ represents H and hydroxyl, ketal, amino, thiols and cyano groups; for the compounds of the general formula (1), (2), (3) and (4), R⁶ represents a methyl group, lipid chains derived from mono and polyunsaturated fatty acids of up to 24 carbon atoms, protein binding site; for the compounds of general formula (3) and (4), Rˣ represents alkyl groups of up to 8 straight or branched chain carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl and octyl, and the isomers string of all the above, when x is different from zero; for the compounds of general formula (3) and (4), Rˣ also represents alkylaryl, alkanoyloxyaryls, alkenyloxyaryls and alkenylaryls groups. The alkyl groups will preferably have up to 8 straight or branched chain carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl and octyl, and the chain isomers of all of the above, when x is different from zero.
First Claim
Family
- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Country Designations
Patent Owner(s)
| Patent Owner | Address |
|---|---|
| CT DE INVESTIGACIÓN Y DESARROLLO DE MEDICAMENTOS | CU |
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Inventor(s)
| Inventor Name | Address |
|---|---|
| YAMILA VERDECIA REYES | CU |
| ESTAEL OCHOA RODRIGUEZ | CU |
| LAURA GARCIA PUPO | CU |
| YANIER NUEZ FIGUEREDO | CU |
| JUAN ENRIQUE TACORONTE MORALES | CU |
Cited Art Landscape
- No Cited Art to Display
Full Text
Legal Events
Matter Detail
Update Public Data
Dismiss
Edit
Save
Renewals Detail
Edit
Save
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Note
The template below is formatted to ensure compatibility with our system.
Provide tags with | separated like (tags1|tags2).
Maximum length is 128 characters for Customer Application No
Mandatory Fields * - 'MatterType','AppType','Country','Title','SerialNo'.
Acceptable Date Format - 'MM/DD/YYYY'.
Acceptable Filing/App Types -
- Continuation/Divisional
- Original
- Paris Convention
- PCT National
- With Priority
- EP Validation
- Provisional Conversion
- Reissue
- Provisional
- Foreign Extension
Acceptable Status -
- Pending
- Abandoned
- Unfiled
- Expired
- Granted
Acceptable Matter Types -
- Patent
- Utility Model
- Supplemental Protection Certificate
- Design
- Inventor Certificate
- Plant
- Statutory Invention Reg
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Success
E-mail has been sent successfully.
Failure
Some error occured while sending email. Please check e-mail and try again!
Important Notes on Latency of Status data
This Status indicator is an estimation based on the relevant document kind code. As such, it status will only indicate "Published" or "Granted". Expired, lapsed or abandoned statuses are not available in this release. Please refer to the legal status information for more information.
This status should not be taken as legal conclusion. No representations are made as to the accuracy of the status provided. Please consult a legal professional before relying on this status information.
Important Note on Priority Date data
This priority date is an estimated earliest priority date and is purely an estimation. This date should not be taken as legal conclusion. No representations are made as to the accuracy of the date listed. Please consult a legal professional before relying on this date.
Only for Granted EP cases
EP validations represent the countries in which the EP patent may be in force. Data is based on reporting from the various EP contracting states. The reporting consistency can vary across the countries.